research papers
Phosphatidylinositol transfer protein α binds microcolins in its open conformation
aInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nam. 2, 166 10 Prague, Czech Republic, and bSection on Molecular Signal Transduction, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
*Correspondence e-mail: [email protected]
Phosphatidylinositol transfer proteins (PITPs) are essential lipid-binding proteins that regulate phosphoinositide signaling, membrane trafficking and autophagy through the transport of phosphatidylinositol and other phospholipids between intracellular membranes. Microcolin compounds have been identified as selective inhibitors of class I PITPs, revealing important roles of PITPs in Hippo signaling and autophagy. Here, we report the of human PITPα in complex with microcolin H at 2.0 Å resolution. The structure enables a detailed description of the interaction between microcolin H and the lipid-binding cavity. Besides the expected to the Cys94 residue, the structure also reveals an extensive network of hydrogen bonds, water bridges and hydrophobic interactions. Importantly, PITPα remains in the open conformation upon binding to microcolin H. Quantitative cavity analysis confirms that the microcolin-bound structure adopts a volume comparable to that of the unliganded PITPα and is markedly larger than that of the lipid-bound state. These findings demonstrate that microcolins selectively trap PITPα in an open conformation and provide a structural basis for their inhibitory mechanism. Furthermore, our results show that ligand binding can profoundly change protein conformation, which underscores the limitation of docking experiments.
Keywords: lipid transport; crystal structure; inhibitors; PITPs.
PDB reference: PITPα, complex with microcolin H, 9ta5
1. Introduction
Phosphatidylinositol transfer proteins (PITPs) are small cytoplasmic proteins capable of transporting specific namely phosphatidylinositol (PI), phosphatidylcholine (PC) or phosphatidic acid (PA), between membranes of intracellular They were discovered in studies showing that soluble proteins can mediate the exchange of between membranes (Wirtz & Zilversmit, 1969
). Since these early studies, enormous progress has been made in revealing the structural and functional features of these proteins (reviewed in Ashlin et al., 2021
; Pathak et al., 2024
). PITPs belong to the Start domain family of lipid-transfer proteins and have been classified based on their molecular architecture and sequence homology (Fig. 1
). There are two class I PITPs, PITPα and PITPβ, coded by two genes, PITPNA and PITPNB, with two splice forms of PITPβ. These are small soluble proteins of ∼32 kDa in size that are capable of transporting either PI or PC bound in their hydrophobic cavities. Class IIA PITPs, which include Nir2 and Nir3, encoded by the PITPNM1 and PITPNM2 genes, are larger, ∼120 kDa proteins that contain several additional domains besides their N-terminal PITP domains. These include an FFAT motif mediating interaction with ER-anchored VAP-A/B proteins, a DDHD domain that is also present in three phospholipase A1 proteins (iPLA1α, iPLA1β and iPLA1γ, also named DDHD1, p125/Sec23IP and DDHD2, respectively) and an LNS2 domain at the C-terminus that mediates binding to PA (see Kim et al., 2025
; Raghu et al., 2021
). Class IIB is represented by RdgBβ, a smaller protein that shows the highest sequence homology to the PITP domains of Nir2 and Nir3 and is encoded by the PITPNC1 gene expressed in two splice forms. Unlike the class I PITPs that bind PI and PC, class II PITPs can bind and transport PI and PA instead (Garner et al., 2012
).
| Figure 1 Domain organization of phosphatidylinositol transfer proteins (PITPs). Schematic representation of the domain architecture of PITP family members classified into class I, class IIA and class IIB. Class I proteins (PITPα and PITPβ splice variants) consist solely of the PITP domain. Class IIA proteins (Nir2/PITPNM1/RdgBαI and Nir3/PITPNM2/RdgBαII) contain an N-terminal PITP domain followed by an FFAT motif, a central DDHD domain and a C-terminal LNS2 domain. Nir1/PITPNM3/RdgBαIII lacks the N-terminal PITP domain but retains the FFAT, DDHD and LNS2 domains. Class IIB proteins (RdgBβ splice variants) consist only of the PITP domain. |
While many studies have explored and characterized the functions and properties of these proteins (reviewed in Ashlin et al., 2021
; Grabon et al., 2019
; Pathak et al., 2024
), the recent identification of microcolin compounds as specific inhibitors of class I PITPs has greatly facilitated the understanding of their functions and revealed their unique importance in Hippo signaling and autophagy (Li et al., 2022
; Yang et al., 2023
). In our recent studies we have reported the structure of PITPα in complex with one of these compounds, VT01454, a synthetic derivative of microcolin B, with improved potency against class I PITPs (Kim et al., 2024
). In another recent report, molecular docking through a computational approach was used to predict the structure of PITPα in complex with various microcolins, including microcolin H (Bailly & Vergoten, 2025
). In the present study, we report the X-ray structure of PITPα in complex with microcolin H and discuss the implications of its structural features as they relate to the lipid-transport function of these proteins.
2. Materials and methods
2.1. Protein expression and purification
The recombinant PITPα protein was expressed as described previously (Kim et al., 2024
) using our standard protocols for lipid-binding/transport proteins (Eisenreichova, Humpolickova et al., 2023
; Eisenreichova, Klima et al., 2023
). Briefly, PITPα was expressed with an N-terminal 6×His tag followed by a SUMO tag. The construct was expressed in Escherichia coli BL21 Star cells, which were induced with 300 µM isopropyl β-D-1-thiogalactopyranoside upon reaching an OD600 of 0.7. After overnight incubation at 18°C, the cells were harvested, resuspended in wash buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol, 20 mM imidazole, 3 mM 2-mercaptoethanol) and lysed by sonication. The clarified lysate was loaded onto Ni–NTA resin and incubated for one hour. Following several washing rounds with wash buffer, the protein was eluted with elution buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol, 300 mM imidazole, 3 mM 2-mercaptoethanol). The His6–SUMO tag was removed by overnight Ulp1 protease digestion (4°C). The protein was subsequently purified by anion-exchange chromatography on a HiTrap Q HP column (Cytiva) in 20 mM Tris pH 8.0 using a NaCl gradient, followed by on a HiLoad 16/600 Superdex 75 pg column (Cytiva) equilibrated in 20 mM Tris pH 7.4. The purified protein was concentrated to 12 mg ml−1 and stored at −80°C.
2.2. Crystallization and crystallographic analysis
For crystallographic analysis, the protein was mixed with microcolin H (MedChemExpress) at a molar ratio of 1:1.5 (protein:inhibitor) and incubated at room temperature for approximately one hour. Crystallization trials were set up using the sitting-drop vapor-diffusion method. Each drop consisted of 150 nl protein–ligand mixture and 150 nl reservoir solution from various commercial screening kits, dispensed using a Mosquito robot (SPT Labtech). Crystals appeared after a week in multiple conditions. However, only crystals from condition C7 of the JCSG IV screen [0.1 M imidazole pH 8, 10%(w/v) PEG 8000] achieved diffraction quality. These crystals were transferred into the reservoir solution supplemented with 20% glycerol for cryoprotection and then flash-cooled in liquid nitrogen.
The crystallographic data set was collected from a single crystal on the BL14.1 beamline at the BESSY II electron-storage ring operated by the Helmholtz-Zentrum Berlin (Mueller et al., 2025
). The data were processed using XDS (Kabsch, 2010
; Sparta et al., 2016
). The structure of PITPα covalently bound to microcolin H was solved by using the structure of PITPα in complex with the inhibitor VT01545 as a search model (PDB entry 8pqo; Kim et al., 2024
) in the program Phaser v.2.8.3 (McCoy et al., 2007
). The obtained initial model was further improved using automatic model refinement with the phenix.refine tool (Afonine et al., 2012
) from the Phenix package v.1.20.1-4487 (Liebschner et al., 2019
) and manual model building with Coot v.0.9.8.7 (Emsley et al., 2010
). Geometrical restraints for the cysteine residue covalently linked to microcolin H were generated with Grade2 v.1.7.1 (Global Phasing). Statistics for data collection and processing, structure solution and refinement are summarized in Table 1
. Structural figures were generated with the PyMOL molecular-graphics system v.2.5.4 (Schrödinger). The finalized coordinates and structure factors have been deposited in the Protein Data Bank (https://www.rcsb.org) under accession code 9ta5. To calculate the cavities presented in Fig. 3, the CavitOmiX PyMOL plugin (v.1.0; Innophore) was used with its default settings except for the following: the grid spacing was set to 1, the probe radius to 2 and the softness to 1.3.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3. Results and discussion
3.1. PITPα–microcolin H complex at atomic resolution
Recent studies revealed that microcolin drugs bind class I PITPs (Pathak et al., 2024
; Yang et al., 2023
; Zhang, 2025
). Here, we selected microcolin H for structural analysis because it was recently identified as an autophagy inducer with antitumor potential, specifically causing autophagic cell death in tumors (Yang et al., 2023
). Furthermore, a recent docking study suggested that microcolin H binds to PITP with the highest in silico affinity among all microcolins tested (Bailly & Vergoten, 2025
).
To obtain the crystal structure of PITPα bound to microcolin H, purified recombinant PITPα was incubated with the compound in a 1.5-fold molar excess. Because microcolins bind irreversibly to a conserved cysteine residue (Cys94) in the center of the cavity (Li et al., 2022
), the mixture was incubated at room temperature for one hour prior to crystallization screening. Crystals formed under multiple conditions; however, diffraction-quality crystals were only obtained from a single condition (see Section 2
). These crystals diffracted to approximately 2 Å resolution and belonged to the orthorhombic space group P212121. The structure was solved by molecular replacement using the PITPα–VT01454 complex (PDB entry 8pqo) as the search model.
Immediately after molecular replacement, clear electron density corresponding to microcolin H was visible (Fig. 2
a). The structure was refined to good geometry and R factors, as detailed in Section 2
and Table 1
. The high resolution allowed us to directly observe the binding of microcolin H to PITPα (Fig. 2
b).
| Figure 2 Crystal structure of the PITPα–microcolin H complex. (a) Overall structure of PITPα with bound microcolin H. Microcolin H is shown with its electron-density map (Fo − Fc map) contoured at 3σ and colored green. (b) Close up-view of the interactions between PITPα and microcolin H. Microcolin H is depicted as orange sticks and PITPα is colored blue. Microcolin H-interacting residues are shown as dark blue sticks. Selected hydrogen bonds are indicated by yellow dashed lines and water molecules involved in water bridges are depicted as red spheres. |
The defining feature of this structure is a that is formed between microcolin H and Cys94, which provides the anchoring point for microcolin H within the binding cavity. This bond is formed by the addition of the cysteine thiol group to the conjugated double bond of the ligand. In principle, this represents a nucleophilic conjugate (Michael) addition. Surrounding this covalent attachment, Gln22 and Lys194 form direct hydrogen bonds to microcolin O atoms. Other residues, including Tyr18, Thr113, His115 and Glu217, form water bridges with the ligand. In addition to these polar contacts, the hydrophobic region of the cavity, physiologically occupied by the acyl chains of the lipid ligands, stabilizes microcolin H through an array of hydrophobic interactions; specifically, with Ile83, Ile98, Phe107, Ile109, Phe221 and Phe224, which promote deep burial of the ligand through nonpolar packing. Together, these covalent, hydrogen-bonding, water-mediated and hydrophobic interactions define a tightly integrated binding interface between PITPα and microcolin H (Fig. 2
b).
3.2. PITPα binds microcolin H in its open conformation
Structural studies have shown that PITPα can adopt two basic conformations, open and closed, which differ mainly in the positioning of the α2 helix and the arrangement of β-strands β2–β4 (Fig. 3
; Yoder et al., 2001
; Tilley et al., 2004
; Schouten et al., 2002
). Intuitively, when the lipid cargo phosphatidylinositol (PI) or phosphatidylcholine (PC) is bound, PITPα assumes the closed conformation (Fig. 3
a; Yoder et al., 2001
; Tilley et al., 2004
). Also intuitively, at one point during the loading of PITPα with its lipid cargo, the protein must be in the unliganded state and be in the open conformation (Fig. 3
b). Only then is the cavity accessible to solvent and poised for lipid exchange. This also means that microcolin drugs can only enter the cavity of the protein at the point of its lipid-exchange cycle. What is somewhat counterintuitive, however, is that after binding of microcolin H there is no closure of the cavity around the drug. Instead, PITPα remains in the open conformation in the microcolin-bound structure (Fig. 3
c), which was also observed previously for PITPα in complex with the inhibitor VT01454 (Kim et al., 2024
).
| Figure 3 Structural comparison of the PITPα–microcolin H complex with previously reported PITPα structures. Structural alignment of the PITPα–microcolin H complex (blue) with (a) PI-bound PITPα (orange; PDB entry 1uw5), (b) mouse unliganded PITPα (pink; PDB entry 1kcm), (c) PC-bound PITPα (green; PDB entry 1t27) and (d) the PITPα–VT01454 complex (gray; PDB entry 8pqo). |
3.3. Analysis of PITPα cavities in the open and closed states
To quantify the differences between various ligand-bound states of PITPα, we calculated the pairwise root-mean-square deviations (r.m.s.d.s) between PITPα structures in the unliganded state and in complex with different ligands. The r.m.s.d. values reveal that PITPα bound to microcolin H or VT01454 is structurally similar to the unliganded protein, indicating that these ligands stabilize a comparable, open conformation. In contrast, substantially larger r.m.s.d.s are observed for comparisons involving PC- or PI-bound structures with unliganded PITPα, reflecting the distinct closed conformation adopted upon lipid binding. Together, these data highlight a clear structural separation between inhibitor-bound/open and lipid-bound/closed states of PITPα (Table 2
).
| ||||||||||||||||||||||||||||||||||||||||||||
Next, we analyzed the volumes of PITPα cavities. Unlike the volumes of regular Euclidean solids, the volume of a protein cavity is not well defined, and the numerical result strongly depends on the algorithm used for its calculation. Typically, such algorithms use a spherical probe of a given diameter, usually similar to that of a water molecule, and determine the positions within the protein structure that can be occupied by this probe. Although this approach is widely accepted, the resulting volume depends on the specific parameters and implementation of the program used. We employed CavitOmiX, a PyMOL plugin, as described in detail in Section 2
. Using these settings, the calculated cavity volumes were 844 Å3 for PI-bound PITPα (the only closed conformation), 2799 Å3 for microcolin H-bound PITPα, 2728 Å3 for unliganded mouse PITPα and 2346 Å3 for VT01454-bound PITPα (Fig. 4
). These results, obtained using an independent approach and without the need to directly observe conformational changes, illustrate that microcolin-bound PITPα adopts the open conformation.
| Figure 4 Binding cavities of PITPα in the microcolin H- and PI-bound states. The microcolin H complex is shown in blue (a). For comparison, the PI-bound PITPα structure is shown as a light-orange cartoon (b), unliganded PITP is in salmon (c) and VT01454-bound PITP is in gray (d). The cavity volume corresponds to the conformation of PITPα. |
Typical methods used to study protein–small-molecule interactions include isothermal titration surface plasmon resonance fluorescence anisotropy and related techniques (Su & Xu, 2018
; Sülzen et al., 2025
; Okamoto & Sako, 2017
; Rezabkova et al., 2010
). These approaches provide binding constants and, in some cases, kinetic parameters or thermodynamic contributions such as enthalpy and entropy (Smola et al., 2021
). However, they do not reveal how a ligand interacts with its target protein at the atomic level. Instead, binding modes are often inferred using computational simulations based on a protein structure determined in an unliganded state or in complex with a different ligand (Gazgalis et al., 2020
; Guterres et al., 2019
). If the protein structure used for modeling does not represent the conformation adopted during binding of the ligand of interest, the resulting simulation results will be highly inaccurate, at best. Our results highlight the importance of determining the correct protein conformation under ligand-bound conditions. Specifically, a docking experiment using the VT01454 inhibitor could not correctly predict the structure as it assumed that the PITP domain was in the closed conformation (Kim et al., 2024
). Similarly, a recent computational study (Bailly & Vergoten, 2025
) used the PC-bound state of the PITP domain to predict microcolin binding to the protein in silico and therefore reached an inaccurate conclusion.
In summary, the structures reported here and in Kim et al. (2024
) showing how microcolins target class I PITPs reveal that these inhibitors stabilize the open conformation of the protein. The importance of this finding is that it allows us to draw some conclusions regarding the functions of these proteins. Previous structural studies showed that class I PITPs are found in a closed conformation when they hold their lipid cargo (Yoder et al., 2001
; Tilley et al., 2004
). To exchange its lipid cargo, the protein must assume an open conformation that must be facilitated by its transient interaction with membranes. In fact, studies with mutant proteins truncated in their C-termini that interfere with closing on their cargo showed that such mutants show significantly stronger membrane binding (Grabon et al., 2017
; Schouten et al., 2002
). Based on these data, access of the inhibitor to the cargo bay of the proteins must take place at the point where the protein interacts with the membrane, i.e. when it presents its open conformation (Schouten et al., 2002
). Our previous data showed that the treatment of cells expressing a GFP-tagged PITPα or PITPβ with the inhibitor VT01454 caused the otherwise cytoplasmic protein to associate with membranes (Kim et al., 2024
). This finding was consistent with the conclusion that even under the conditions of live cell experiments, the inhibitor replaces the lipid cargo when the PITP interacts with the membrane, and by stabilizing the open conformation it causes the protein to remain membrane-bound. It is important to note that without permanent binding, which takes place with these inhibitors, the open conformation and membrane interaction is extremely short-lived and transient, as previously suggested by molecular-dynamics simulation studies (Grabon et al., 2017
). The current results showing that another covalently bound inhibitor also promotes the open conformation gives further support to this model of structural transition during lipid exchange at the membrane.
Acknowledgements
We thank the Helmholtz-Zentrum Berlin für Materialien und Energie for the allocation of synchrotron-radiation beamtime. We would particularly like to acknowledge Frank Lennartz and Petr Pachl for help and support during the experiment.
Funding information
This research was supported by the project `New Technologies for Translational Research in Pharmaceutical Sciences'/NETPHARM, project ID CZ.02.01.01/00/22_008/0004607 (co-funded by the European Union).
References
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012). Acta Cryst. D68, 352–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Ashlin, T. G., Blunsom, N. J. & Cockcroft, S. (2021). Biochim. Biophys. Acta, 1866, 158985. CrossRef Google Scholar
Bailly, C. & Vergoten, G. (2025). Future Pharmacol. 5, 13. CrossRef Google Scholar
Eisenreichova, A., Humpolickova, J., Różycki, B., Boura, E. & Koukalova, A. (2023). Biochimie, 215, 42–49. CrossRef CAS PubMed Google Scholar
Eisenreichova, A., Klima, M., Anila, M., Koukalova, A., Humpolickova, J., Różycki, B. & Boura, E. (2023). Cells, 12, 1974. CrossRef PubMed Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Garner, K., Hunt, A. N., Koster, G., Somerharju, P., Groves, E., Li, M., Raghu, P., Holic, R. & Cockcroft, S. (2012). J. Biol. Chem. 287, 32263–32276. CrossRef CAS PubMed Google Scholar
Gazgalis, D., Zaka, M., Abbasi, B. H., Logothetis, D. E., Mezei, M. & Cui, M. (2020). ACS Omega, 5, 14297–14307. CrossRef CAS PubMed Google Scholar
Grabon, A., Bankaitis, V. A. & McDermott, M. I. (2019). J. Lipid Res. 60, 242–268. Web of Science CrossRef CAS PubMed Google Scholar
Grabon, A., Orłowski, A., Tripathi, A., Vuorio, J., Javanainen, M., Róg, T., Lönnfors, M., McDermott, M. I., Siebert, G., Somerharju, P., Vattulainen, I. & Bankaitis, V. A. (2017). J. Biol. Chem. 292, 14438–14455. CrossRef CAS PubMed Google Scholar
Guterres, H., Lee, H. S. & Im, W. (2019). J. Chem. Theory Comput. 15, 6524–6535. CrossRef CAS PubMed Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Kim, D., Lee, S., Jun, Y. & Lee, C. (2025). Proc. Natl Acad. Sci. USA, 122, e2516849122. CrossRef PubMed Google Scholar
Kim, Y. J., Pemberton, J. G., Eisenreichova, A., Mandal, A., Koukalova, A., Rohilla, P., Sohn, M., Konradi, A. W., Tang, T. T., Boura, E. & Balla, T. (2024). EMBO J. 43, 2035–2061. CrossRef CAS PubMed Google Scholar
Li, F. L., Fu, V., Liu, G. B., Tang, T., Konradi, A. W., Peng, X., Kemper, E., Cravatt, B. F., Franklin, J. M., Wu, Z. M., Mayfield, J., Dixon, J. E., Gerwick, W. H. & Guan, K. L. (2022). Nat. Chem. Biol. 18, 1076–1086. CrossRef CAS PubMed Google Scholar
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877. Web of Science CrossRef IUCr Journals Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
Mueller, U., Barthel, T., Benz, L. S., Bon, V., Crosskey, T., Genter Dieguez, C., Förster, R., Gless, C., Hauss, T., Heinemann, U., Hellmig, M., James, D., Lennartz, F., Oelker, M., Ovsyannikov, R., Singh, P., Wahl, M. C., Weber, G. & Weiss, M. S. (2025). J. Synchrotron Rad. 32, 766–778. Web of Science CrossRef CAS IUCr Journals Google Scholar
Okamoto, K. & Sako, Y. (2017). Curr. Opin. Struct. Biol. 46, 16–23. CrossRef CAS PubMed Google Scholar
Pathak, A., Willis, K. G., Bankaitis, V. A. & McDermott, M. I. (2024). Biochim. Biophys. Acta, 1869, 159529. CrossRef Google Scholar
Raghu, P., Basak, B. & Krishnan, H. (2021). Biochim. Biophys. Acta, 1866, 158984. CrossRef Google Scholar
Rezabkova, L., Boura, E., Herman, P., Vecer, J., Bourova, L., Sulc, M., Svoboda, P., Obsilova, V. & Obsil, T. (2010). J. Struct. Biol. 170, 451–461. Web of Science CrossRef CAS PubMed Google Scholar
Schouten, A., Agianian, B., Westerman, J., Kroon, J., Wirtz, K. W. A. & Gros, P. (2002). EMBO J. 21, 2117–2121. CrossRef PubMed CAS Google Scholar
Smola, M., Gutten, O., Dejmek, M., Kožíšek, M., Evangelidis, T., Tehrani, Z. A., Novotná, B., Nencka, R., Birkuš, G., Rulíšek, L. & Boura, E. (2021). Angew. Chem. Int. Ed. 60, 10172–10178. CrossRef CAS Google Scholar
Sparta, K. M., Krug, M., Heinemann, U., Mueller, U. & Weiss, M. S. (2016). J. Appl. Cryst. 49, 1085–1092. Web of Science CrossRef CAS IUCr Journals Google Scholar
Su, H. & Xu, Y. (2018). Front. Pharmacol. 9, 1133. CrossRef PubMed Google Scholar
Sülzen, H., Klima, M., Duchoslav, V. & Boura, E. (2025). Biophys. Chem. 319, 107392. PubMed Google Scholar
Tilley, S. J., Skippen, A., Murray-Rust, J., Swigart, P. M., Stewart, A., Morgan, C. P., Cockcroft, S. & McDonald, N. Q. (2004). Structure, 12, 317–326. CrossRef PubMed CAS Google Scholar
Wirtz, K. W. & Zilversmit, D. B. (1969). Biochim. Biophys. Acta, 193, 105–116. CrossRef CAS PubMed Google Scholar
Yang, H., Zhang, X., Wang, C., Zhang, H., Yi, J., Wang, K., Hou, Y., Ji, P., Jin, X., Li, C., Zhang, M., Huang, S., Jia, H., Hu, K., Mou, L. & Wang, R. (2023). Signal Transduct. Target. Ther. 8, 428. CrossRef PubMed Google Scholar
Yoder, M. D., Thomas, L. M., Tremblay, J. M., Oliver, R. L., Yarbrough, L. R. & Helmkamp, G. J. (2001). J. Biol. Chem. 276, 9246–9252. CrossRef PubMed CAS Google Scholar
Zhang, J. (2025). Mar. Drugs, 23, 283. CrossRef PubMed Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

journal menu
access



